Boehringer Ingelheim (Canada) Ltd. announced today that on June 24, 2015 Health Canada approved Ofev (nintedanib) to treat idiopathic pulmonary fibrosis (IPF) in adults. Ofev has been clinically proven to reduce the decline in lung function in IPF patients.

IPF is a debilitating and fatal lung disease, which causes progressive, irreversible scarring of the lungs, resulting in lung function decline and difficulty breathing. There is no cure. There are approximately 5,000 to 15,000 Canadians currently living with IPF, and the approval of Ofev offers IPF patients a new treatment option to manage this fatal disease.

“The approval of Ofev is a significant advancement for IPF patients, offering a proven treatment option to people living with this disease,” says Dr. Martin Kolb, M.D. PhD, Director, Division of Respirology at McMaster University. “Not only does Ofev offer another treatment choice for IPF patients to manage their disease, it has been shown to significantly reduce the risk of adjudicated acute exacerbations, which can be deadly.”

For more details, go to: http://www.boehringer-ingelheim.ca/en/news/press_releases/2015/06Jul2015111.html